(Q52652744)

5 May 2018

title

Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness. (English)

1 reference

5 May 2018

author

Pierre-Francois Cartron

6

1 reference

5 May 2018

Pascal Bonnet

object named as

Pascal Bonnet

3

0 references

author name string

Mathilde Cheray

1

1 reference

5 May 2018

Arulraj Nadaradjane

2

1 reference

5 May 2018

Sylvain Routier

4

1 reference

5 May 2018

François M Vallette

5

1 reference

5 May 2018

publication date

1 June 2014

1 reference

5 May 2018

published in

Epigenomics

1 reference

5 May 2018

volume

6

1 reference

5 May 2018

issue

3

1 reference

5 May 2018

page(s)

267-275

1 reference

5 May 2018

Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation

cites work

1 reference

Advances in the computational development of DNA methyltransferase inhibitors

21 January 2018

1 reference

Natural products as DNA methyltransferase inhibitors: a computer-aided discovery approach

21 January 2018

1 reference

Inhibitors of DNA methyltransferases: insights from computational studies

21 January 2018

1 reference

Molecular modeling of inhibitors of human DNA methyltransferase with a crystal structure: discovery of a novel DNMT1 inhibitor

21 January 2018

1 reference

Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors

21 January 2018

1 reference

DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies

21 January 2018

1 reference

DNA methylation inhibitors in cancer: recent and future approaches

21 January 2018

1 reference

Procainamide is a specific inhibitor of DNA methyltransferase 1.

21 January 2018

1 reference

DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters

21 January 2018

1 reference

The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA

21 January 2018

1 reference

Disruption of Dnmt1/PCNA/UHRF1 interactions promotes tumorigenesis from human and mice glial cells

21 January 2018

1 reference

Direct observation of individual endogenous protein complexes in situ by proximity ligation

21 January 2018

1 reference

Specific inhibition of one DNMT1-including complex influences tumor initiation and progression.

21 January 2018

1 reference

The USP7/Dnmt1 complex stimulates the DNA methylation activity of Dnmt1 and regulates the stability of UHRF1

21 January 2018

1 reference

CFP1 interacts with DNMT1 independently of association with the Setd1 Histone H3K4 methyltransferase complexes

21 January 2018

1 reference

STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes

21 January 2018

1 reference

Regulation of normal cell cycle progression by flavin-containing oxidases.

21 January 2018

1 reference

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation

21 January 2018

1 reference

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

Small molecule inhibitors of the p53-MDM2.

21 January 2018

1 reference

PCNA clamp facilitates action of DNA cytosine methyltransferase 1 on hemimethylated DNA

21 January 2018

1 reference

The epigenetic regulator Cfp1.

21 January 2018

1 reference

Usp7 and Uhrf1 control ubiquitination and stability of the maintenance DNA methyltransferase Dnmt1

21 January 2018

1 reference

Cfp1 integrates both CpG content and gene activity for accurate H3K4me3 deposition in embryonic stem cells

21 January 2018

1 reference

Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection.

21 January 2018

1 reference

Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/EPI.14.18

1 reference

5 May 2018

1 reference

5 May 2018